ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,473.17
-0.25%
Dow Jones
39,134.76
0.77%
US Dollar vs MXN
18.3558
0.01%
Brent Oil
84.925
-0.09%
Bitcoin
64,906.19
0.13%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Invitae Corporation (NVTA)

  7. Invitae Corporation (NVTA) Noticias

NVTA Invitae Corporation

0.0891
0.00 (0.00%)
19 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Invitae Corporation NVTA NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 0.0891 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.0891 0.0891
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
06/3/202407:31EDGAR2Form 8-K - Current report
06/2/202416:07EDGAR2Form 8-K - Current report
30/1/202406:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
29/1/202415:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202415:34EDGAR2Form 8-K/A - Current report: [Amend]
22/1/202406:05EDGAR2Form 8-K - Current report
22/1/202406:00PRNUSInvitae Completes Sale of Reproductive Health Assets to..
18/1/202415:10EDGAR2Form 8-K - Current report
21/12/202320:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/12/202320:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202315:29EDGAR2Form 8-K - Current report
13/12/202315:07PRNUSInvitae Divests Ciitizen Health Data Platform and Implements..
11/12/202315:41EDGAR2Form 8-K - Current report
17/11/202315:48EDGAR2Form 8-K - Current report
15/11/202315:22EDGAR2Form 8-K - Current report
14/11/202318:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/11/202318:55EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/11/202315:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202315:05EDGAR2Form 8-K - Current report
08/11/202315:01PRNUSInvitae Reports Third Quarter 2023 Financial Results
06/11/202315:00PRNUSInvitae Launches Enhanced Chemistry of MRD Test to Better..
01/11/202305:59PRNUSInvitae to Announce Third Quarter 2023 Financial Results on..
25/10/202310:00PRNUSLandmark Study Reveals Magnitude of Uncertain Results in..
20/10/202317:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202315:38EDGAR2Form 8-K - Current report
19/10/202315:30PRNUSInvitae Appoints Dr. David Sholehvar as Chief Operating..
12/10/202315:15PRNUSRural Hospital System Demonstrates the Clinical Benefits of..
10/10/202315:30PRNUSInvitae to Present Data at the National Society of Genetic..
03/10/202311:07PRNUSInvitae's Common Hereditary Cancers Panel Receives FDA..
02/10/202320:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202319:47EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/9/202319:00DJNFDA Gives Marketing Authorization to Invitae Test for Cancer..
27/9/202315:29EDGAR2Form 8-K - Current report
25/9/202317:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202315:30PRNUSInvitae Announces Appointment of Finance Veteran Ana Schrank..
22/9/202316:02EDGAR2Form 8-K - Current report
22/9/202315:30PRNUSInvitae Receives Notice of Non-Compliance with NYSE Minimum..
14/9/202316:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/8/202315:02PRNUSInvitae Hires Industry Veteran Robert Guigley as Chief..
23/8/202307:12EDGAR2Form 8-K - Current report
15/8/202306:30PRNUSClinical Trial Results Support Genetic Testing of All..
14/8/202315:02PRNUSInvitae Announces Selection of Finance Executive Robert..
10/8/202315:03EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
10/8/202315:01EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
09/8/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
09/8/202308:22EDGAR2Form POS AM - Post-Effective amendments for registration..
09/8/202308:20EDGAR2Form POS AM - Post-Effective amendments for registration..
08/8/202315:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202315:09EDGAR2Form 8-K - Current report
08/8/202315:01PRNUSInvitae Reports Second Quarter 2023 Financial Results

Su Consulta Reciente

NYSE
NVTA
Invitae
BTHB
DAIKRW
Dai Stablecoin
EU
BPIE
BPCE 2.255% until12mar40
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados